ADMA BIOLOGICS, INC.
No SEC Form 4 filings for $ADMA in the last 30 days.
See all $ADMA insider activity →ADMA BIOLOGICS, INC. (ADMA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20079311_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update 2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year 2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year
ADMA Biologics (NASDAQ:ADMA) faces a securities fraud class action after its shares fell about 29%, following Culper Research allegations of channel stuffing tied to reported 20% 2025 growth. The complaint cites potential violations of Sections 10(b) and 20(a). ADMA stock dropped from $13.59 (Mar 23, 2026) to $9.63 (Mar 25) after the report.
Bleichmar Fonti & Auld LLP said a securities fraud class action was filed against ADMA Biologics (NASDAQ:ADMA) and executives, alleging federal securities law violations tied to Culper Research claims of channel stuffing. The suit cites a March 24, 2026 16.6% drop after a report alleging undisclosed related-party distributor activity. Investors have until Aug. 10, 2026 to seek lead-plaintiff status.
Over the past 7 days, alphai's AI scored 2 news stories mentioning ADMA (ADMA BIOLOGICS, INC.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent ADMA coverage spans financial news, regulation and earnings.
Guidance reiteration plus stronger ASCENIV utilization narrative can support near-term sentiment, but investors will still scrutinize sustainability amid U.S. IG pricing pressure.
The lawsuit adds legal and reputational risk around alleged revenue inflation, which can pressure the stock and increase volatility.
New lawsuit increases litigation and disclosure-risk premium for ADMA, with potential for further negative sentiment and volatility.
The filing raises litigation and potential disclosure-integrity risk for ADMA, which can pressure sentiment and increase downside tail risk.
The filing raises fraud and disclosure-control risk around ASCENIV revenue recognition, which can pressure valuation and increase litigation overhang.
alphai scores every news story that mentions ADMA with an AI model for sentiment and relevance, and aggregates insider trades from ADMA BIOLOGICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ADMA BIOLOGICS, INC. (ADMA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20079311_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update 2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year 2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year
4 min readADMA Biologics (NASDAQ:ADMA) faces a securities fraud class action after its shares fell about 29%, following Culper Research allegations of channel stuffing tied to reported 20% 2025 growth. The complaint cites potential violations of Sections 10(b) and 20(a). ADMA stock dropped from $13.59 (Mar 23, 2026) to $9.63 (Mar 25) after the report.
4 min readBleichmar Fonti & Auld LLP said a securities fraud class action was filed against ADMA Biologics (NASDAQ:ADMA) and executives, alleging federal securities law violations tied to Culper Research claims of channel stuffing. The suit cites a March 24, 2026 16.6% drop after a report alleging undisclosed related-party distributor activity. Investors have until Aug. 10, 2026 to seek lead-plaintiff status.
3 min readHagens Berman announced a securities fraud class action against ADMA Biologics, Inc. (NASDAQ: ADMA) for alleged misstatements about its financial condition, revenue recognition, inventory distribution, and business practices. The suit covers Aug. 9, 2024 to Mar. 25, 2026, with an Aug. 10, 2026 lead plaintiff deadline, alleging channel stuffing, related-party transactions, and weak internal controls.
3 min readSueWallSt reports a securities class action involving ADMA Biologics (NASDAQ: ADMA). ADMA projected about 20% ASCENIV revenue growth for 2025 and reported $362.5 million in 2025 ASCENIV net revenues. According to Culper Research, absent alleged channel stuffing, ASCENIV revenue would have declined about 3%. Lead plaintiff deadline is Aug. 10, 2026.
4 min readBleichmar Fonti & Auld LLP says it filed a securities fraud class action against ADMA Biologics (NASDAQ:ADMA) and executives after ADMA shares fell about 29% following Culper Research’s channel-stuffing allegations tied to reported 20% 2025 growth and ASCENIV. The complaint cites Sections 10(b) and 20(a) and names Mazzarino v. ADMA Biologics, No. 26-cv-6918, with an Aug. 10, 2026 lead-plaintiff deadline.
4 min readKessler Topaz Meltzer & Check said a securities-fraud class action was filed against ADMA Biologics (NASDAQ: ADMA) in the District of New Jersey for purchases between Aug. 9, 2024 and Mar. 25, 2026. Allegations include undisclosed related-party transactions, channel stuffing, and weak internal controls. The firm cites a March 24 Culper Research report tied to a 29.1% stock drop on Mar. 25. Lead plaintiff deadline: Aug. 10, 2026.
4 min readThe article claims ADMA Biologics received an FDA label expansion for its ASCENIV product, but it provides no additional details or figures. The rest is promotional content for an “Insider Monkey” newsletter, citing broad AI/robotics themes and alleging a prior stock call (British American Tobacco) returned 90% in 16 months.
2 min readADMA Biologics said the FDA approved an expansion of ASCENIV’s label to include pediatric patients aged 2 and older, previously limited to primary humoral immunodeficiency/PI patients aged 12+. The company attributed the change to completion of a required post-marketing pediatric assessment and said it broadens access for younger immune-compromised patients.
3 min readGrossman Jerrold B purchased 6,400 shares of ADMA BIOLOGICS, INC. (ADMA) at $7.91 on 2026-05-27.
1 min read
